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Prophylactic
Antibiotic
Conventional
Antibiotics
P
value
Total Number of Patients 36 37
Autologous 10 14
Allogeneic Cord Blood 10 9
Allogeneic Bone Marrow 16 14
Positive Blood Cultures 28 29
Gram Positive Total (#Patients) 24 (7) 27 (10)
Gram Negative Total (#Patients) 5 (1) 2 (2)
Mean Discharge Day 43.29 34.74 0.13
Autologous 23.40 18.73 0.99
Allogeneic Cord Blood 62.50 52.80 0.27
Allogeneic Bone Marrow 43.20 35 0.80
Days of Fever 8.71 11.31 0.28
Autologous 7.89 6.46 0.70
Allogeneic 9.72 14.32 0.14
PICU Admission 7 3
Need for Pressors 3 3
Clostridium difﬁcile Diarrhea 6 4
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received melphalan 200 mg/m2. The incidence and grade of
OM were assessed in both groups using the WHO grading
system.
Results: A total of 247 consecutive patients were identiﬁed.
In the FBT cohort, 26 patients received SCPR and 122 pa-
tients received palifermin for OM prophylaxis. In the
Melphalan cohort, 68 patients received SCPR and 31 pa-
tients received palifermin for OM prophylaxis. In the FBT
cohort, the incidence of grade 3 or 4 OM was signiﬁcantly
lower in the palifermin compared to SCPR group (57% vs
100%, OR¼0.19, p<0.0001). The overall incidence of OMwas
lower in the palifermin compared to SCPR group (86% vs
100%, OR¼0.42, p¼0.06). In the melphalan cohort, the
incidence of grade 3 or 4 OM was signiﬁcantly lower in the
SCPR compared to the palifermin group (12% vs 35%,
OR¼0.24, p¼0.008). The overall incidence of OM was lower
in the SCPR compared to the palifermin group (28% vs 58%,
OR¼0.28, p¼0.005).
Conclusion: While palifermin is more effective than SCPR in
preventing FBT-induced OM, SCPR appears more effective in
preventingmelphalan-induced OM. These ﬁndings challenge
the current accepted biological model that views OM as a
universal outcome regardless of the causative agent. We
propose individualized selection of OM prophylactic agent
based on the type of conditioning therapy.293
Prophylactic Broad Spectrum Antibiotics at the Onset of
Neutropenia in HSCT Do Not Change the Number of
Febrile Days or Duration of Hospitalization
Hilary Haines. Pediatrics, Division of Pediatric Hematology/
Oncology, University of Alabama Birmingham, Birmingham, AL
There is increased interest in the use of broad spectrum an-
tibiotics at the onset of neutropenia during hematopoietic
stem cell transplant to prevent serious bacterial infections. In
2009, our group instituted the use of cefepime starting when
the ANC decreased to < 500 as one quality improvement
measure to help reduce the number of serious bacterial in-
fections. This is a preliminary analysis on the efﬁcacy of this
intervention.
All patients undergoing a hematopoietic stem cell trans-
plant from January 2008 to December 2011 were included in
this retrospective analysis. Assignment of patients to each
group was based on intent to treat with 36 patients to have
broad spectrum antibiotic initiated at the onset of neu-
tropenia or with fevers (prophylactic antibiotic group) and
37 patients had antibiotics initiated only for febrile episodes
(conventional antibiotic group). There was no difference
between the two groups in days post transplant for
discharge and number of days of fever. There was a trend
towards a decreased number of febrile days in allogeneic
patients only although this was not statistically signiﬁcant.
8 patients in the prophylactic antibiotic group and 11 pa-
tients conventional antibiotic group had positive blood
culture results at some point during their immediate post-
transplant courses, the majority of which were gram posi-
tive infections. There were 3 deaths prior to hospital
discharge in the conventional antibiotic group, one of sepsis
secondary to vancomycin resistant enterococcus and the
remaining 2 died of respiratory failure due to pulmonary
hemorrhage. There was one death of pulmonary hemor-
rhage associated with refractory GVHD in the prophylactic
antibiotic group.
Despite the fact that there was a decrease in the number of
patients with bacterial infections, preliminary data from thispatient population does not yet indicate an overwhelming
improvement in patient outcomes following the use of pro-
phylactic cefepime at the onset of neutropenia, perhaps due
to the relative infrequency of gram negative bacterial in-
fections. Additional information in a larger number of pa-
tients, including patterns of antibiotic resistance and
duration of antibiotics, may help to deﬁne whether prophy-
lactic antibiotics initiated at the onset of neutropenia change
outcomes.294
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Respiratory virus infections are recognized as an important
complication in hematopoietic stem cell transplantation
(HSCT). Respiratory syncytial virus (RSV), inﬂuenza, and
parainﬂuenza have been associated with high morbidity and
mortality post HSCT. Despite an increasing number of re-
ports, knowledge regarding risk factors and long term pul-
monary complications are still very limited. Therefore, we
report our study to evaluate incidence and outcome of res-
piratory virus infections following HSCT in a large pediatric
transplant centre.
Eight hundred and forty four children received HSCT during
the study period (January 2000 and August 2012). The
number of patients undergoing allogeneic (allo) transplant
was 489 and autologous (auto) was 355. Thirty-ﬁve patients
(4.2%) were found to have respiratory virus infection diag-
nosed by a nasopharyngeal aspirate (NPA) in the ﬁrst
100 days post HSCT. Among these, 22 (63%) and 13 (37%)
were allo and auto HSCT recipients, respectively. Upper and
lower respiratory tract infection were documented in 19
(54.3%) and 16 (45.7%) patients, respectively. The viruses
identiﬁed were parainﬂuenza 37%, inﬂuenza 26%, RSV 23%,
adenovirus 11%, and human metapneumovirus 3%. None of
the patients had signiﬁcant respiratory symptoms prior to
HSCT.
